Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Clinicopathological features of 149 patients who were treated with preoperative chemotherapy

From: Clinical verification of the relationship between smoking and the immune microenvironment of breast cancer

Parameters (n = 149) Number of patients (%)
Age (years old) 56 (24–75)
Tumour size (mm) 27.6 (10.2–98.0)
Skin infiltration
 Negative/positive 134 (89.9%)/15 (10.1%)
Lymph node metastasis
 N0/N1/N2/N3 51 (34.2%)/54 (36.2%)/29 (19.5%)/15 (10.1%)
HER2
 Negative/positive 87 (58.4%)/62 (41.6%)
Ki67
 Negative/positive 23 (15.4%)/126 (84.6%)
ORR
 Non-responders/responders 11 (7.4%)/138 (92.6%)
pCR
 Negative/positive 75 (50.3%)/74 (49.7%)
Recurrence
 Negative/positive 123 (82.6%)/26 (17.4%)
TILs
 Low/high 58 (38.9%)/91 (61.1%)
Smoker
 No/yes 105 (70.5%)/44 (29.5%)
Pack-years of smokers 20 (2.5–135)
Pack-years
 Low/high 106 (71.1%)/43 (28.9%)
  1. HER human epidermal growth factor receptor, ORR objective response rate, pCR pathological complete response, TILs tumour-infiltrating lymphocytes